Edwards Lifesciences Corp (EW)vsIntegra LifeSciences Holdings (IART)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
IART
Integra LifeSciences Holdings
$16.99
-3.25%
HEALTHCARE · Cap: $1.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 283% more annual revenue ($6.30B vs $1.64B). EW leads profitability with a 17.4% profit margin vs -30.1%. IART appears more attractively valued with a PEG of 0.71. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
IART
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Margin of Safety
+86.2%
Fair Value
$81.09
Current Price
$16.99
$64.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
2.4% revenue growth
0.4% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : IART
The strongest argument for IART centers on Price/Book, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : IART
The primary concerns for IART are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.96 is elevated, increasing financial risk.
Key Dynamics to Monitor
EW profiles as a growth stock while IART is a turnaround play — different risk/reward profiles.
IART carries more volatility with a beta of 1.08 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
IART generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 52/100), backed by strong 17.4% margins and 16.7% revenue growth. IART offers better value entry with a 86.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Integra LifeSciences Holdings
HEALTHCARE · MEDICAL DEVICES · USA
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?